Multi-Center Study Evidences Greater AE Risks with PK13 Inhibitor use in B-Cell Malignancy-based Clinical Trials Sample

Multi-Center Study Evidences Greater AE Risks with PK13 Inhibitor use in B-Cell Malignancy-based Clinical Trials Sample

A multi-center research team from universities and health systems revealed that treatment with phosphatidylinositol 3-kinase inhibitors improves survival for patients with B cell malignancies however also increases incidents of adverse events including pneumonitis,...

Pin It on Pinterest